Preview

Oncohematology

Advanced search
Fullscreen

For citations:


Mingalimov M.A., Baryak E.A., Misyurin A.V., Kesaeva L.A., Mkrtchyan A.S., Misyurina E.N., Donskoy M.A., Tolstykh T.N., Orlova M.S., Chudnova T.S., Ivanova D.D., Kochneva O.L., Zotina E.N., Makeshova A.B., Andreev S.S., Yatskov K.V., Samsonova I.V., Lysenko M.A. Experience with acalabrutinib as a component of molecularly adapted antitumor therapy according to the R-CHOP-X protocol in patients with newly diagnosed diffuse large B-cell lymphoma. Oncohematology. 2025;20(3):22-26. (In Russ.) https://doi.org/10.17650/1818-8346-2025-20-3-22-26

Views PDF (Rus): 1


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1818-8346 (Print)
ISSN 2413-4023 (Online)